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cline proved cost-saving or cost effective in relation to the alter-
natives studied. Overall, a gain of about 78–200 thousand life
years (LYG) or 88–226 thousand quality-adjusted life years
(QALYs) can be obtained in a long-term. The incremental cost-
effectiveness ratio (ICER) is 2.330 EUR per LYG (2.073 per
QALY) and 1.781 EUR per LYG (1584 per QALY) compared to
unaided cessation or bupropion, respectively. Varenicline is a
dominant strategy compared to NRT. Even if the savings from
avoided smoking-related diseases are ignored and the time
horizon will be reduced to 20 years, varenicline remains cost-
effective with ICER under 18.000 EUR per LYG and QALY
compared to all other alternatives. CONCLUSION: The results
corroborate the ﬁndings of health beneﬁts and favourable cost-
effectiveness of smoking cessation pharmacotherapy from former
studies.
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OBJECTIVES: Prior to use in an international study, the Insulin
Treatment Satisfaction Questionnaire (ITSQ) and the Environ-
mental Tobacco Smoke Questionnaire (ETS-Q) underwent lin-
guistic validation in 10 and 6 languages respectively. The original
scales containing 22 and 3 items were developed in US and UK
English respectively. Rigorous methodology was required to
ensure conceptual equivalence and cultural relevance across dif-
ferent languages. METHODS: The translation process was con-
ducted by a specialist in each target country using the following
standardized methodology: 1) two forward translations by pro-
fessional translators; 2) comparison and reconciliation of the
translations by the specialist in the target country; 3) backward
translation; 4) comparison of source and backward version; 5)
review by a clinician (for the ITSQ only); and 6) comprehension
test on a small sample of the target population diagnosed with
diabetes and undergoing insulin treatment (for the ITSQ only).
RESULTS: Linguistic and conceptual issues emerged during the
translation process. Firstly, when an original item used two adjec-
tives to cover one concept some languages only had one term to
express this. Secondly, some concepts, in particular in relation to
meals, do not exist in certain Indian languages and paraphrases
had to be found to ensure conceptual equivalence with the origi-
nal and appropriateness in the target language. CONCLUSION:
The language versions of the ITSQ and the ETS-Q were estab-
lished according to rigorous translation methodology. The
process aims to ensure conceptual equivalence across different
language versions to facilitate international comparison and
pooling of data. Thus, the result is linguistically validated ques-
tionnaires. The linguistic validation process as a whole supports
the advantage of integrating international feedback on concepts
and wording before a questionnaire is ﬁnalized.
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NICOTINE PATCHES
Shi CW, Ganiats T
UC San Diego, La Jolla, CA, USA
OBJECTIVES: Little is known about how the public uses the
nicotine patch after it was reclassiﬁed from prescription to over-
the-counter (OTC) status. This observational study describes the
characteristics of consumers who purchase OTC nicotine patches
from pharmacies and to determine factors associated with off-
label use of nicotine patch. METHODS: Prospective, longitudi-
nal study of N = 600 OTC nicotine patch consumers from a
random sample of 30 retail pharmacies throughout San Diego
County. Each subject completed a self-administered, anonymous
questionnaire at the time of purchase and at 2-weeks after using
the patch. Off-label use was deﬁned as intention to smoke while
on the patch or using the patch for harm reduction rather than
quitting. Logistic regression was performed to determine the
factors associated with off-label use. RESULTS: The cohort had
low Fagerstrom nicotine dependence score (mean = 3.58). Sixty-
four percent stated that their physicians were not aware of them
using the patch. Main reasons prompting purchase included self-
initiative (54%), family/friends (20%), physician advice (15%),
and pharmacist’s advice (3%). Eight percent intend to use the
patch for harm reduction rather than quitting. Minorities and
individuals with high income were more likely to engage in
off-label use. Of those who returned the second questionnaire
(N = 155), 78% did not review the self-aid counseling materials
enclosed in the product package. Forty-ﬁve percent reported
smoking cigarettes at 2 weeks, and 8% admitted to using more
than one patch per day. CONCLUSION: A substantial number
of the consumers had low Fagerstrom nicotine dependence scores
and would not have qualiﬁed as for the patch under the prescrip-
tion setting. Most consumers did not review the self-aid materials
even though it was included in the package, and some consumers
intentionally engaged in off-label use of the product. Further
research is needed to devise interventions to ensure proper usage
of OTC nicotine patch by the public.
SURGERY—Cost Studies
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OBJECTIVES: To evaluate the cost-effectiveness of PPH com-
pared to MM for treating prolapsed internal haemorrhoids from
the NHS’s perspective. METHODS: A cohort-based model with
a decision tree structure was developed to investigate the cost
effectiveness of PPH in the treatment of haemorrhoids; the
primary outcome was total direct NHS cost and QALYs. Patients
in whom surgical intervention is considered appropriate enter the
model having undergone either a PPH or MM procedure. The
patient then goes through a recovery period during which a
proportion of the patients may suffer a recurrent prolapse. The
severity of the recurrent prolapse determines whether the patient
is able to self-treat or requires further surgery. Those who require
re-surgery are readmitted to hospital and undergo the same pro-
cedure they had on entry to the model. Resource utilisation
associated with procedure cost and post operative complication
was estimated by NHS reference costs 2006. RESULTS: Cost
drivers were identiﬁed as the cost of the stapling device and
reductions in length of stay in the PPH group. QALYs were
driven by reductions in post-operative pain from PPH. Total
direct NHS costs per were 972.66 and 928.66 for PPH and
MM, respectively. PPH vs. MM offers a cost saving of 10.74/
patient due to less length of stay and OR time considering the
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initial surgical procedure, and an incremental cost after one year
of 43.70. QALYs were 0.7675 and 0.7591 (PPH vs. MM,
respectively). The ICER for PPH vs MM was estimated at
5188.09 per QALY. Probabilistic sensitivity analysis demon-
strated the results to be robust. CONCLUSION: PPH is a valu-
able alternative to MM in patients where surgical intervention is
indicated. Efﬁcacious without compromising QoL, whilst
decreasing length of stay and OR time, PPH can be considered a
cost-effective procedure for prolapsed internal haemorrhoids.
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OBJECTIVES: This study evaluated the cost-effectiveness of ITS
versus current POPM choices in Greece from the hospital per-
spective. METHODS: Two hundred, forty-nine surgeons and
anesthesiologists were interviewed to derive the most frequent
treatment sequences for POPM for patients experiencing moder-
ate to severe post-surgical pain. These were: a) 2 days intrave-
nously administrated (IV) opioids, 2 days IV non opioids, 1 day
oral non-opioids; b) 2 days intramuscularly administrated (IM)
opioids, 2 days IV non-opioids, 1 day oral non-opioids; c) 2 days
epidural, 3 days oral non-opioids. A decision analytic model was
developed to estimate costs and effectiveness of each these
sequential treatment arms, from surgery to discharge, compared
with 2 days of ITS followed by 3 days of oral non-opioids.
Effectiveness data were obtained from ITS trials and published
literature. The resource utilisation was deﬁned by the same phy-
sician interviews and a Delphi Panel of 40 Greek physicians.
Costs included pain medication and cost of POPM-related com-
plications not covered by or exceeding the daily reimbursed
amount to the hospital, the hotel costs and ﬁnally staff time
estimated during four European Delphi Panels. The complica-
tions’ cost was estimated by the Greek Delphi panel. Sensitivity
analyses (30%) were performed on the cost of complications
and staff time estimations. RESULTS: The probability of a suc-
cessful treatment (adequate pain control and no complications)
was 76% for ITS, 49% for the ﬁrst two treatment sequencies and
72% for the third. Total cost per patient was 677–717€ for ITS
and €717, €704, €770 for the three sequences respectively. ITS
was associated with reduced staff time and fewer complications.
The model was robust with low-moderate sensitivity (€10
change of base results). CONCLUSION: The treatment sequence
of ITS dominated the currently practiced POPM treatments in
Greece indicating that ITS cost was offset by savings resulting
from reduced staff time and fewer complications.
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OBJECTIVES: Evidence on the health care costs of laparoscopic
versus open surgery remains inconclusive. Previous work has
largely used charge data to measure cost, whereas a more rel-
evant metric would be the actual transactions amounts paid.
While studies have quantiﬁed the association between surgical
site infections (SSI) and cost, there is little evidence on the
broader measure of nosocomial infections (SSI, UTI, blood and
respiratory infections). To address these issues, this study exam-
ined the effects of laparoscopic versus open surgery and nosoco-
mial infections on direct health care costs for three common
surgical procedures: cholecystectomy, hysterectomy, and appen-
dectomy. METHODS: Hospital discharge abstract data were
obtained for 4489 subjects in 10 hospitals who were treated for
cholecystectomy, hysterectomy, or appendectomy via laparo-
scopic or open procedures. Multivariable regression analyses
were performed to estimate the relationships between laparo-
scopic surgery, nosocomial infections and health care costs for
these three procedures. The models also controlled for the fol-
lowing confounders: disease severity, age, gender, insurance
status and hospital. RESULTS: Laparoscopic surgery signiﬁ-
cantly reduces the cost of these surgical procedures. For all
patients, laparoscopic surgery reduces the health care costs of
surgery by $1796 (p < 0.01). For cholecystectomies alone, lap-
aroscopic surgery reduces these costs by even more—$2457
(p < 0.01). Laparoscopic surgery reduces costs for hysterectomy
by $1888 (p < 0.01) and appendectomy by $1019 (p < 0.05)
Nosocomial infections have a large and signiﬁcant effect on costs,
increasing overall costs by $3591 (p < 0.01). The increased costs
of nosocomial infections are greatest for cholecystectomies
($5009, p < 0.01), followed by appendectomies ($3185,
p < 0.01) and hysterectomies ($2581, p < 0.01). CONCLU-
SION: Laparoscopic surgery and nosocomial infections are
major cost drivers for each of these procedures. Laparoscopic
surgery substantially reduces the costs to payers for cholecystec-
tomies, hysterectomies, and appendectomies; whereas nosoco-
mial infections have a large positive effect on transaction costs
for all three procedures.
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OBJECTIVES: In abdominal aortic aneurysm (AAA) an endo-
vascular procedure (EVAR) was introduced challenging the gold
standard of open repair (OR). RCTs comparing them from 1999
onwards showed beneﬁt in 30-day mortality for EVAR. Due to
additional experience with EVAR; complication rates and
resource consumption may have improved. The aim of this study
is to assess the efﬁcacy, safety and resource use in the ﬁrst year
post EVAR in a current population compared to the EVAR
populations included in RCTs. METHODS: Efﬁcacy, safety and
resource use data were collected retrospectively for patients
undergoing EVAR from 2004, with at least one year follow-up.
Patient population was designed to match the published trials in
terms of age, AAA size, and suitability for surgery. Descriptive
statistics were used with normative data, mean, minimum and
maximum value, number of patients with valid data and 95%
conﬁdence intervals calculated for continuous and frequencies
for discrete data. RESULTS: A total of 149 patients’ records from
UK and Dutch hospitals were analyzed. Patients in the study
were similar in terms of age and gender to the published trials,
but higher proportion had additional risk factors (diabetes,
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